Message #10 From:
NewsBot Date: September 11, 2006 08:15:00 AM
PHLI News Dutton Associates Announces Investment Opinion: PacificHealth Laboratories Rated Speculative Buy In Initiating Coverage By Dutton Associates
EL DORADO HILLS, Calif.--(BUSINESS WIRE)--Sept. 11, 2006--Dutton Associates initiates coverage on PacificHealth Laboratories (OTCBB:PHLI) with a Speculative Buy rating and a $2.00 price target. The 13-page report by Dutton senior analyst Jon Ziegler, CFA is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Reuters, and other leading financial portals.
PacificHealth Laboratories is an innovative company in health care that focuses on the discovery, development and commercialization of patented protein-based nutrition products that stimulate specific peptides involved in appetite regulation and that activate biochemical pathways involved in muscle performance and growth. PacificHealth Laboratories principle areas of research include weight loss, management of Type II diabetes and sports performance. In February 2006, it concluded a $4 million agreement with Mott's, LLP, a division of Cadbury Schweppes Americas Beverages (CSAB). In this agreement, the Company sold its patents, trademarks and intellectual properties for its ACCELERADE(R) and ENDUROX R4(R) sports nutrition products for development into a ready-to-drink form and licensed back, on a royalty free basis, the right to continue marketing the powder and gel forms of these products. The CSAB agreement, as well as the impending launch of the Company's new appetite suppressant diet product, has dramatically changed the Company's current financial and future growth prospects. Based on the competitive nature of the sports drink market, it is anticipated that CSAB will spend between $30-$50 million behind the marketing and promotion of ACCELERADE RTD. This should have a positive impact on the sales of the powder and gel forms marketed by PacificHealth Laboratories.
About Dutton Associates
Dutton Associates is one of the largest independent investment research firms in the U.S. Its 31 senior analysts are primarily CFAs and have expertise in many industries. Dutton Associates provides continuing analyst coverage of over 140 enrolled companies, and its research, estimates, and ratings are carried in all the major databases serving institutions and online investors.
The cost of enrollment in our one-year continuing research program is US $39,500 prepaid for 4 Research Reports, typically published quarterly, and requisite Research Notes. Dutton Associates received $35,000 from the Company for 4 Research Reports with coverage commencing on 9/11/2006. We do not accept payment of our fees in company stock. Our principals and analysts are prohibited from owning or trading in securities of covered companies. The views expressed in this research report accurately reflect the analyst's personal views about the subject securities or issuer. Neither the analyst's compensation nor the compensation received by us is in any way related to the specific ratings or views contained in this research report or note. Please read full disclosures and analyst background at www.jmdutton.com before investing.
